Indications
Vimkunya is indicated for active immunisation for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. The use of this vaccine should be in accordance with official recommendations.
Composition
- Active substance
- Chikungunya virus (CHIKV) virus-like particle (VLP) proteins (capsid protein (C) and envelope proteins E1 and E2) derived from CHIKV Senegal strain 37997 produced in human embryonic kidney cells by recombinant DNA technology, adsorbed on aluminium hydroxide, hydrated
- International name (INN)
- Chikungunya vaccine (recombinant, adsorbed)
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vimkunya
- Therapeutic area
- Chikungunya virus
- Marketing authorisation holder
- Bavarian Nordic A/S
- Status
- Authorised
- EU authorisation
- 28 Feb 2025
- EMA product number
- EMEA/H/C/005470
EMA designations
- Orphan medicine
- No
- Conditional approval
- No
- Biosimilar
- No
- Generic
- No
- Accelerated assessment
- No
- Additional monitoring
- Yes
- Patient safety information
- No